688373 Stock Overview
A biopharmaceutical company, discovers, develops, and commercialize drugs for unmet medical needs.
Snowflake Score | |
---|---|
Valuation | 0/6 |
Future Growth | 2/6 |
Past Performance | 0/6 |
Financial Health | 6/6 |
Dividends | 0/6 |
Shanghai MicuRx Pharmaceutical Co., Ltd. Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | CN¥4.46 |
52 Week High | CN¥8.27 |
52 Week Low | CN¥3.23 |
Beta | 0.78 |
11 Month Change | 15.54% |
3 Month Change | -3.88% |
1 Year Change | -33.43% |
33 Year Change | n/a |
5 Year Change | n/a |
Change since IPO | -59.01% |
Recent News & Updates
Shareholder Returns
688373 | CN Biotechs | CN Market | |
---|---|---|---|
7D | 1.1% | 1.7% | 2.7% |
1Y | -33.4% | -10.5% | 4.6% |
Return vs Industry: 688373 underperformed the CN Biotechs industry which returned -10.5% over the past year.
Return vs Market: 688373 underperformed the CN Market which returned 4.6% over the past year.
Price Volatility
688373 volatility | |
---|---|
688373 Average Weekly Movement | 7.6% |
Biotechs Industry Average Movement | 8.7% |
Market Average Movement | 7.5% |
10% most volatile stocks in CN Market | 11.4% |
10% least volatile stocks in CN Market | 5.2% |
Stable Share Price: 688373 has not had significant price volatility in the past 3 months compared to the CN market.
Volatility Over Time: 688373's weekly volatility (8%) has been stable over the past year.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
2007 | 188 | Yuan Zhengyu | www.micurxchina.com |
Shanghai MicuRx Pharmaceutical Co., Ltd., a biopharmaceutical company, discovers, develops, and commercialize drugs for unmet medical needs. It is developing Contezolid (MRX-I) and Contezoilid acefosamil (MRX-4) oxazolidinone antibiotics for multidrug-resistant gram-positive bacteria; MRX-8 MRX, a polymyxin antibiotic, to target multidrug-resistant Gram-negative bacteria; MRX-5 for multidrug-resistant gram-negative bacteria; MRX-7 for multidrug-resistant gram-positive bacteria; MRX-15 and MRX-17 to treat kidney disease; MRX-18 for the treatment of COVID-19; and MRX-23 for the treatment of tumour. Shanghai MicuRx Pharmaceutical Co., Ltd.
Shanghai MicuRx Pharmaceutical Co., Ltd. Fundamentals Summary
688373 fundamental statistics | |
---|---|
Market cap | CN¥2.92b |
Earnings (TTM) | -CN¥497.31m |
Revenue (TTM) | CN¥109.40m |
26.7x
P/S Ratio-5.9x
P/E RatioIs 688373 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
688373 income statement (TTM) | |
---|---|
Revenue | CN¥109.40m |
Cost of Revenue | CN¥20.06m |
Gross Profit | CN¥89.34m |
Other Expenses | CN¥586.65m |
Earnings | -CN¥497.31m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
Oct 25, 2024
Earnings per share (EPS) | -0.76 |
Gross Margin | 81.66% |
Net Profit Margin | -454.56% |
Debt/Equity Ratio | 27.8% |
How did 688373 perform over the long term?
See historical performance and comparison